Sogol Mostoufi-Moab1, Emmanuel Labourier2, Lisa Sullivan3, Virginia LiVolsi4, Yimei Li5, Rui Xiao5, Sylvie Beaudenon-Huibregtse2, Ken Kazahaya6,7, N Scott Adzick8, Zubair Baloch4, Andrew J Bauer9. 1. 1 Division of Oncology, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania. 2. 2 Asuragen, Inc. , Austin, Texas. 3. 3 Division of Anatomic Pathology, Department of Pathology. 4. 4 Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania. 5. 5 Department of Biostatistics and Epidemiology, University of Pennsylvania , Philadelphia, Pennsylvania. 6. 6 Division of Pediatric Otolaryngology, Department of Pediatric Surgery, University of Pennsylvania , Philadelphia, Pennsylvania. 7. 7 Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania , Philadelphia, Pennsylvania. 8. 8 Division of General Surgery, Department of Pediatric Surgery, University of Pennsylvania , Philadelphia, Pennsylvania. 9. 9 Division of Endocrinology and Diabetes, Department of Pediatrics, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Thyroid nodules are less common in pediatric patients (i.e., those ≤18 years) than they are in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in preoperative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses. METHODS: This was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC. Molecular testing was performed by multiplex qualitative polymerase chain reaction followed by bead array cytometry. Oncogene results were analyzed for association with age, sex, histology, lymph node metastasis, and intrathyroidal spread. RESULTS: A mutation in one of the 17 molecular markers evaluated was found in: 2/6 (33%) FTC, 8/24 (33%) fvPTC, 17/27 (63%) cPTC, and 4/8 (50%) dsvPTC. Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC. BRAF was the most common mutation in cPTC (12/17; 71%), and RET/PTC was the only mutation associated with dsvPTC. Overall, a mutation was found in 32/68 (47%) malignant specimens, with a single follicular adenoma positive for PAX8/PPARG. The relative distribution of gene alterations in pediatric lesions was similar to adults. The presence of a BRAF mutation in pediatric cPTC did not predict a more invasive phenotype. CONCLUSIONS: Of 33 nodules with genetic alterations, 32 were malignant. Mutations in RAS were most frequently associated with FTC, RET/PTC rearrangements with dsvPTC, and invasive fvPTC, and BRAF with cPTC. These results suggest a clinical role for mutational analysis of pediatric nodules to guide the surgical approach.
BACKGROUND: Thyroid nodules are less common in pediatric patients (i.e., those ≤18 years) than they are in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in preoperative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses. METHODS: This was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC. Molecular testing was performed by multiplex qualitative polymerase chain reaction followed by bead array cytometry. Oncogene results were analyzed for association with age, sex, histology, lymph node metastasis, and intrathyroidal spread. RESULTS: A mutation in one of the 17 molecular markers evaluated was found in: 2/6 (33%) FTC, 8/24 (33%) fvPTC, 17/27 (63%) cPTC, and 4/8 (50%) dsvPTC. Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC. BRAF was the most common mutation in cPTC (12/17; 71%), and RET/PTC was the only mutation associated with dsvPTC. Overall, a mutation was found in 32/68 (47%) malignant specimens, with a single follicular adenoma positive for PAX8/PPARG. The relative distribution of gene alterations in pediatric lesions was similar to adults. The presence of a BRAF mutation in pediatric cPTC did not predict a more invasive phenotype. CONCLUSIONS: Of 33 nodules with genetic alterations, 32 were malignant. Mutations in RAS were most frequently associated with FTC, RET/PTC rearrangements with dsvPTC, and invasive fvPTC, and BRAF with cPTC. These results suggest a clinical role for mutational analysis of pediatric nodules to guide the surgical approach.
Entities:
Keywords:
oncogene testing; pediatric thyroid cancer
Authors: Thomas Rio Frio; Amin Bahubeshi; Chryssa Kanellopoulou; Nancy Hamel; Marek Niedziela; Nelly Sabbaghian; Carly Pouchet; Lucy Gilbert; Paul K O'Brien; Kim Serfas; Peter Broderick; Richard S Houlston; Fabienne Lesueur; Elena Bonora; Stefan Muljo; R Neil Schimke; Dorothée Bouron-Dal Soglio; Jocelyne Arseneau; Kris Ann Schultz; John R Priest; Van-Hung Nguyen; H Rubén Harach; David M Livingston; William D Foulkes; Marc Tischkowitz Journal: JAMA Date: 2011-01-05 Impact factor: 56.272
Authors: Leomar Y Ballester; Stephen F Sarabia; Hadi Sayeed; Nimesh Patel; Joshua Baalwa; Ioanna Athanassaki; Jose A Hernandez; Erica Fang; Norma M Quintanilla; Angshumoy Roy; Dolores H López-Terrada Journal: Pediatr Dev Pathol Date: 2015-09-14
Authors: Jennifer L Picarsic; Melissa A Buryk; John Ozolek; Sarangarajan Ranganathan; Sara E Monaco; Jeffrey P Simons; Selma F Witchel; Nursen Gurtunca; Judith Joyce; Shan Zhong; Marina N Nikiforova; Yuri E Nikiforov Journal: Pediatr Dev Pathol Date: 2015-09-14
Authors: Victoria Casado-Medrano; Alison O'Neill; Stephen Halada; Theodore W Laetsch; Andrew J Bauer; Aime T Franco Journal: Cancer Genet Date: 2022-03-06
Authors: Aime T Franco; Julio C Ricarte-Filho; Amber Isaza; Zachary Jones; Neil Jain; Sogol Mostoufi-Moab; Lea Surrey; Theodore W Laetsch; Marilyn M Li; Jessica Clague DeHart; Erin Reichenberger; Deanne Taylor; Ken Kazahaya; N Scott Adzick; Andrew J Bauer Journal: J Clin Oncol Date: 2022-01-11 Impact factor: 50.717
Authors: Adam Stenman; Samuel Backman; Klara Johansson; Johan O Paulsson; Peter Stålberg; Jan Zedenius; C Christofer Juhlin Journal: Endocr Relat Cancer Date: 2021-04-29 Impact factor: 5.678
Authors: Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958